January 2026 · 12 min read · Reviewed by Decima Medical Team
If your orthopedic surgeon has recommended a total knee replacement, you deserve a complete picture of your options before you decide. This is not a piece telling you surgery is bad or stem cells are a miracle. It is an honest, evidence-based comparison of two approaches to knee osteoarthritis — because the decision is consequential and the information you need to make it well is often not given to you by the people making money from each option.
Total knee replacement (TKR) is one of the most common elective surgeries in the United States, with approximately 700,000 procedures per year. The outcomes for severe osteoarthritis (Grade 3-4 on the Kellgren-Lawrence scale) are generally good: most patients report significant pain reduction and functional improvement at 12 months. The 15-year implant survival rate is approximately 90%.
However, a frequently cited 2015 study in NEJM found that for mild to moderate osteoarthritis, TKR outcomes were not significantly better than intensive physical therapy at 12 months. The revision rate (needing a second surgery) is 5-10% within 10 years. Recovery is substantial: 6-12 weeks before resuming normal activity, and full recovery can take 12 months.
The evidence for MSC therapy in knee osteoarthritis is promising but must be characterized accurately: it is strongest for mild to moderate disease (Grade 1-2 KL), weaker for severe disease, and still lacks the long-term data that surgery has. A 2022 meta-analysis of 23 RCTs found statistically significant improvement in pain and function scores at 6 and 12 months compared to placebo or hyaluronic acid injection.
The practical advantages: no general anesthesia, same-day procedure, 24-48 hour recovery, no implant with a finite lifespan, and the possibility (not certainty) of cartilage regeneration. The disadvantages: less long-term data, higher out-of-pocket cost, and weaker evidence for severe disease.
For Grade 1-2 knee osteoarthritis: stem cell therapy is a reasonable first-line option before surgery, with a meaningful evidence base and a favorable risk profile. For Grade 3-4: surgery remains the better-evidenced option for most patients, though stem cell therapy may delay the timeline. We will tell you which category you fall into and give you an honest recommendation — even if that recommendation is surgery.
This article is for educational purposes only. Stem cell therapies are investigational. Consult a qualified physician before making any medical decisions.